
IndraLab
Statements
sparser
"First, co-transfection of haemagglutinin epitope tagged-MIB2 (HA-MIB2) [ xref ], CYLD (untagged) and His 6 -ubiquitin expression constructs clearly drove the ubiquitylation of CYLD compared to cells transfected with CYLD and His 6 -ubiquitin (Figure xref panel (i), compare lanes 1 and 2), suggesting that MIB2 may ubiquitylate CYLD."
sparser
"A proposed model explaining how p62 mutations lead to the Paget's disease of bone is the following: mutations of the UBA domain cause an impairment in the interaction between p62 and ubiquitinated TRAF6 and/or CYLD, an enzyme deubiquitinating TRAF6, which in turn enhances the activation of the NF-κB signaling pathway and the resulting increased osteoclastogenesis (Figure 3(b)) [160]."
sparser
"Our results, so far, suggest a model in which E6, in its capacity to function as part of an E3 ubiquitin ligase complex, ubiquitinates CYLD, and does so more efficiently under hypoxic conditions, thereby extinguishing the inhibitory effects of CYLD on the NF-κB pathway and leading to heightened NF-κB activation (see schematic, xref )."
sparser
"CYLD knockdown by siRNA results in constitutive ubiquitination of TRAF2. xref Constitutive ubiquitination of several other CYLD targets have also been detected in CYLD KO cells. xref , xref , xref Furthermore, CYLD mutations seem to contribute to the constitutive activation of NF- κ B in multiple myeloma cells. xref , xref Additional evidence suggests that CYLD is functionally inactivated during signal-induced NF- κ B activation."
sparser
"A proposed model explaining how p62 mutations lead to the Paget's disease of bone is the following: mutations of the UBA domain cause an impairment in the interaction between p62 and ubiquitinated TRAF6 and/or CYLD, an enzyme deubiquitinating TRAF6, which in turn enhances the activation of the NF- κ B signaling pathway and the resulting increased osteoclastogenesis ( xref ) [ xref ]."